This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"

39 views
June 12, 2024

Chapters

NEO-TIM Trial & Drug Combination Overview

00:00

Study Design, Patient Enrollment & Baseline Characteristics

01:40

Clinical Trial Results & Safety Evaluation

04:04

Comments 0
Login to view comments. Click here to Login